Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 29 Myeloid 18 Classical hematology 3 Thoracic 2 Lymphoid 2 Dermatologic 2 Sarcoma 1 Other solid neoplasm 1 NET 1 Genitourinary 1 Endocrine 1 CNS 1 Breast 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 29 Magnetic Resonance Spectroscopy 15 Everolimus 10 pembrolizumab 9 Specimen Handling 9 cabozantinib 7 Nivolumab 7 Lutetium-177 6 surufatinib 5 lenvatinib 5 Octreotide 5 Capecitabine 5 177Lu-octreotide, DOTA(0)-Tyr(3)- 5 olaparib 4 lanreotide 4 gallium Ga 68 dotatate 4 amino-acid, glucose, and electrolyte solution 4 X-Rays 4 Lutetium 4 Ipilimumab 4 Injections 4 Fluorodeoxyglucose F18 4 copper dotatate CU-64 3 atezolizumab 3 Temozolomide 3 Cyclophosphamide 3 Carboplatin 3 pasireotide 2 fludarabine phosphate 2 fludarabine 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

decitabine and cedazuridine drug combination × NET × 1 year × Clear all

NCT05178693 2025-11-24

LANTana

Imperial College London

Phase 1 Recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡